Lipid Management and Peripheral Arterial Disease

Author(s): S. S. Daskalopoulou, M. E. Daskalopoulos, D. P. Mikhailidis, C. D. Liapis

Journal Name: Current Drug Targets

Volume 8 , Issue 4 , 2007

Become EABM
Become Reviewer
Call for Editor


Peripheral arterial disease (PAD) is a common disorder usually associated with silent or symptomatic arterial disease elsewhere in the circulation and a “cluster” of cardiovascular risk factors (e.g. smoking, dyslipidemia, hypertension, and insulin resistance/ diabetes mellitus). The medical management of PAD should focus on both the relief of symptoms and prevention of secondary cardiovascular complications. This approach must include smoking cessation, optimal cholesterol levels, blood pressure and glycemic control as well as prescribing antiplatelet therapy. This review focuses on the evidence supporting the use of lipid-lowering drugs in PAD. Several trials indicate that getting low density lipoprotein-cholesterol levels to target ( < 2.6 mmol/l; 100 mg/dl), or even lower, is associated with improvement of symptoms and a reduction in vascular events in patients with PAD.

Keywords: Peripheral arterial disease, risk factors, dyslipidemia, lipid lowering, statins, prevention

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Published on: 01 March, 2012
Page: [561 - 570]
Pages: 10
DOI: 10.2174/138945007780362737
Price: $65

Article Metrics

PDF: 2